China Approves Akeso and Summit Therapeutics' Ivonescimab for Lung Cancer Treatment

Key Facts

In a move reflecting the rapid evolution of the global biotechnology sector, Akeso, a partner of Summit Therapeutics, announced it has received marketing authorization from China's NMPA for ivonescimab. This approval allows the use of the bispecific antibody as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC). The regulatory milestone follows positive clinical data demonstrating the drug's efficacy when combined with chemotherapy.

This approval strengthens Akeso's position in the Chinese market, while Summit Therapeutics benefits from licensing rights to develop the candidate in specific territories, highlighting the importance of cross-border pharmaceutical partnerships. According to market data, Akeso's stock (9926.HK) closed at 101.5 HKD on August 10, 2026, with daily trading ranging between 101.1 HKD and 105.5 HKD.

Investors should monitor the price levels of 9926.HK, which stood at 101.5 HKD (close of August 10, 2026) to gauge continued market reaction to this authorization. Looking at the economic calendar, while no direct healthcare catalysts are upcoming, recent Chinese trade data from August 7, 2026, showed a surplus of 112.5 billion, reflecting the broader macroeconomic environment in which these firms operate.